Health Care/Hospital
Andall Biosciences Introduces 23WELL: A Breakthrough New Brand with Ovary Care Capsules (1+1) as its Stellar Debut Product
SHANGHAI, May 8, 2024 /PRNewswire/ -- Andall Biosciences Inc. (ABI), a renowned biotechnology company at the forefront of life science research and applications, has made a significant stride with the introduction of their groundbreaking new product line, 23WELL. The brand takes center stage with...
2024-05-08 18:11
1193
Research Results on Jolly Good's Medical VR Will Be Presented for the First Time in the U.S. - Revealing Training VR for HALO Procedures at Large-Scale VR Seminar, SAEM2024
BROOKLINE, Mass., May 7, 2024 /PRNewswire/ -- Jolly Good US Inc. is proud to announce the groundbreaking debut of research findings on its Medical Virtual Reality (VR) platform inthe United States. This unveiling will take place at the annual meeting of the Society for Academic Emergency Medicine...
2024-05-08 02:00
1490
"Momcozy Village" Campaign Elevates Support for Mothers with Upcoming Events and Initiatives
NEW YORK, May 7, 2024 /PRNewswire/ -- As we approach Mother's Day, Momcozy
2024-05-07 22:30
1324
FDA Grants Orphan Drug Designation to 9MW2821
SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...
2024-05-07 22:00
1191
Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024
Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...
2024-05-07 21:08
1564
Mr. Kong, Nano Labs' Chairman and CEO, Increased His Shareholding in the Company
HANGZHOU, China , May 7, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that Mr. Jianping Kong, the Company's chairman and chief executive officer, inf...
2024-05-07 21:00
2378
GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024
YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
2024-05-07 13:27
1359
Datasea Pre-Announces Estimated Revenue of $12.5 Million for April 2024 Supporting its Prior Revenue Guidance of $86 Million for Fiscal 2024
DTSS on Track to Achieve Record Revenue for Fiscal 2024 as it Further Penetrates China's$528 Billion 5G Market BEIJING, May 6, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada and engaged in innovative business seg...
2024-05-06 22:00
2329
German car manufacturer visits HoneyNaps, a South Korean sleep tech company, to develop new automotive healthcare applications
Monitoring biosignals for both drivers and passengers - Analyzing and diagnosing with FDA-approved algorithm SEOUL, South Korea, May 6, 2024 /PRNewswire/ -- Amid the rapid advancement in automobile healthcare and digital healthcare markets, global car manufacturers are racing to adopt cutting ed...
2024-05-06 22:00
1397
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...
2024-05-03 19:00
2335
Zepp Health's Amazfit Unveils Bip 5 Unity: Elevating Health and Style Every Step of the Way
MILPITAS, Calif., May 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp
Health") (NYSE:ZEPP
2024-05-02 23:00
2273
Boryung Launches 2024 Humans In Space Challenge: Sending Experiments into Orbit
* Boryung to support the launch of space experiments into orbit for selected startups and researchers * Held for the third consecutive year, HIS presents an expanded ecosystem of engagements with NASA, ISS National Lab,MIT, and major space companies * Humans In Space(HIS) will serve as a glo...
2024-05-02 20:00
1658
Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers
Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...
2024-05-02 07:01
1766
Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry
BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...
2024-05-01 17:14
1360
135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management
GUANGZHOU, China, May 1, 2024 /PRNewswire/ -- In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from theMedicines, Health Products and Medical Devices secto...
2024-05-01 13:40
1503
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint
BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...
2024-05-01 08:59
1462
Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations
SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...
2024-04-30 23:00
2563
Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World
THE HAGUE, Netherlands, April 30, 2024 /PRNewswire/ -- The 12th Microbiome and Probiotics R&D and Business Collaboration Forum was held with great fanfare in The Hague, Netherlands from April 23rd to 24th, 2024. This prestigious conference is a leading event in the probiotics sector, drawing toget...
2024-04-30 21:09
1617
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...
2024-04-30 20:55
1590
A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...
2024-04-30 20:16
1591
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5214
